Literature DB >> 34366761

Inorganic Nanomaterial-Mediated Gene Therapy in Combination with Other Antitumor Treatment Modalities.

Guanyou Lin1, Richard A Revia1, Miqin Zhang1.   

Abstract

Cancer is a genetic disease originating from the accumulation of gene mutations in a cellular subpopulation. Although many therapeutic approaches have been developed to treat cancer, recent studies have revealed an irrefutable challenge that tumors evolve defenses against some therapies. Gene therapy may prove to be the ultimate panacea for cancer by correcting the fundamental genetic errors in tumors. The engineering of nanoscale inorganic carriers of cancer therapeutics has shown promising results in the efficacious and safe delivery of nucleic acids to treat oncological diseases in small-animal models. When these nanocarriers are used for co-delivery of gene therapeutics along with auxiliary treatments, the synergistic combination of therapies often leads to an amplified health benefit. In this review, an overview of the inorganic nanomaterials developed for combinatorial therapies of gene and other treatment modalities is presented. First, the main principles of using nucleic acids as therapeutics, inorganic nanocarriers for medical applications and delivery of gene/drug payloads are introduced. Next, the utility of recently developed inorganic nanomaterials in different combinations of gene therapy with each of chemo, immune, hyperthermal, and radio therapy is examined. Finally, current challenges in the clinical translation of inorganic nanomaterial-mediated therapies are presented and outlooks for the field are provided.

Entities:  

Keywords:  combinatorial therapy; gene delivery; inorganic nanomaterials; nanomedicine; tumors

Year:  2020        PMID: 34366761      PMCID: PMC8336227          DOI: 10.1002/adfm.202007096

Source DB:  PubMed          Journal:  Adv Funct Mater        ISSN: 1616-301X            Impact factor:   18.808


  262 in total

Review 1.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

Authors:  Yves Pommier; Elisabetta Leo; HongLiang Zhang; Christophe Marchand
Journal:  Chem Biol       Date:  2010-05-28

2.  Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer.

Authors:  Juan R Cubillos-Ruiz; Jason R Baird; Amelia J Tesone; Melanie R Rutkowski; Uciane K Scarlett; Ana L Camposeco-Jacobs; Jorge Anadon-Arnillas; Noah M Harwood; Murray Korc; Steven N Fiering; Lorenzo F Sempere; Jose R Conejo-Garcia
Journal:  Cancer Res       Date:  2012-02-03       Impact factor: 12.701

Review 3.  Challenges in carrier-mediated intracellular delivery: moving beyond endosomal barriers.

Authors:  Martin P Stewart; Anna Lorenz; James Dahlman; Gaurav Sahay
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2015-11-05

4.  Nuclear envelope assembly after mitosis.

Authors:  I C Marshall; K L Wilson
Journal:  Trends Cell Biol       Date:  1997-02       Impact factor: 20.808

5.  Biodegradable hybrid mesoporous silica nanoparticles for gene/chemo-synergetic therapy of breast cancer.

Authors:  Beibei Zhang; Qi Liu; Mengyuan Liu; Peipei Shi; Lichong Zhu; Lu Zhang; Ruifang Li
Journal:  J Biomater Appl       Date:  2019-03-16       Impact factor: 2.646

6.  Zinc Oxide Nanoparticle-Poly I:C RNA Complexes: Implication as Therapeutics against Experimental Melanoma.

Authors:  Meghana Ramani; Miranda C Mudge; R Tyler Morris; Yuntao Zhang; Stanislaw A Warcholek; Miranda N Hurst; Jim E Riviere; Robert K DeLong
Journal:  Mol Pharm       Date:  2017-02-14       Impact factor: 4.939

Review 7.  Therapeutic vaccines for cancer: an overview of clinical trials.

Authors:  Ignacio Melero; Gustav Gaudernack; Winald Gerritsen; Christoph Huber; Giorgio Parmiani; Suzy Scholl; Nicholas Thatcher; John Wagstaff; Christoph Zielinski; Ian Faulkner; Håkan Mellstedt
Journal:  Nat Rev Clin Oncol       Date:  2014-07-08       Impact factor: 66.675

8.  Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells.

Authors:  Raquel T Lima; Luís M Martins; José E Guimarães; Clara Sambade; M Helena Vasconcelos
Journal:  Cancer Gene Ther       Date:  2004-05       Impact factor: 5.987

9.  Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis.

Authors:  Myra E van Linde; Cyrillo G Brahm; Philip C de Witt Hamer; Jaap C Reijneveld; Anna M E Bruynzeel; W Peter Vandertop; Peter M van de Ven; Michiel Wagemakers; Hiske L van der Weide; Roelien H Enting; Annemiek M E Walenkamp; Henk M W Verheul
Journal:  J Neurooncol       Date:  2017-07-20       Impact factor: 4.130

10.  Radiosurgery for brainstem metastases with and without whole brain radiotherapy: clinical series and literature review.

Authors:  Louise Murray; Cynthia Menard; Gelareh Zadeh; Karolyn Au; Mark Bernstein; Barbara-Ann Millar; Normand Laperriere; Caroline Chung
Journal:  J Radiat Oncol       Date:  2016-10-27
View more
  2 in total

Review 1.  The emergence of nanoporous materials in lung cancer therapy.

Authors:  Deepika Radhakrishnan; Shan Mohanan; Goeun Choi; Jin-Ho Choy; Steffi Tiburcius; Hoang Trung Trinh; Shankar Bolan; Nikki Verrills; Pradeep Tanwar; Ajay Karakoti; Ajayan Vinu
Journal:  Sci Technol Adv Mater       Date:  2022-07-20       Impact factor: 7.821

2.  Chitosan-Crosslinked Low Molecular Weight PEI-Conjugated Iron Oxide Nanoparticle for Safe and Effective DNA Delivery to Breast Cancer Cells.

Authors:  Guanyou Lin; Jianxi Huang; Mengyuan Zhang; Shanshan Chen; Miqin Zhang
Journal:  Nanomaterials (Basel)       Date:  2022-02-09       Impact factor: 5.076

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.